210 related articles for article (PubMed ID: 37386620)
1. Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes.
Feng B; Yu P; Yu H; Qian B; Li Y; Sun K; Shi B; Zhang N; Xu G
Diabetol Metab Syndr; 2023 Jun; 15(1):141. PubMed ID: 37386620
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
[TBL] [Abstract][Full Text] [Related]
3. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate-activated Citrate Synthase.
Zhang X; Wang N; Fu P; An Y; Sun F; Wang C; Han X; Zhang Y; Yu X; Liu Y
J Cardiovasc Pharmacol; 2023 Nov; 82(5):375-388. PubMed ID: 37643027
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
6. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
8. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
Drugs Context; 2023; 12():. PubMed ID: 36660013
[TBL] [Abstract][Full Text] [Related]
9. Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial.
Scheffer M; Driessen-Waaijer A; Hamdani N; Landzaat JWD; Jonkman NH; Paulus WJ; van Heerebeek L
ESC Heart Fail; 2020 Dec; 7(6):4478-4487. PubMed ID: 33073523
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction.
Cavka L; Bencak Ferko U; Pitz N; Trpkovski Z; Lainscak M
ESC Heart Fail; 2021 Aug; 8(4):2631-2636. PubMed ID: 34102028
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway.
Li L; Li Q; Huang W; Han Y; Tan H; An M; Xiang Q; Zhou R; Yang L; Cheng Y
Front Pharmacol; 2021; 12():589273. PubMed ID: 34093169
[TBL] [Abstract][Full Text] [Related]
12. Multi-omics approach for identification of molecular alterations of QiShenYiQi dripping pills in heart failure with preserved ejection fraction.
Huang Y; Zhang K; Wang X; Guo K; Li X; Chen F; Du R; Li S; Li L; Yang Z; Zhuo D; Wang B; Wang W; Hu Y; Jiang M; Fan G
J Ethnopharmacol; 2023 Oct; 315():116673. PubMed ID: 37268257
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin restores diabetes-associated decline in vasculogenic capacity of endothelial progenitor cells via activating AMPK-mediated inhibition of inflammation and oxidative stress.
Luo L; Dong B; Zhang J; Qiu Y; Liu X; Zhou Z; He J; Zhang X; Chen L; Xia W
Biochem Biophys Res Commun; 2023 Sep; 671():205-214. PubMed ID: 37302296
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell RNA Sequencing Reveals Metabolic Stress-Dependent Activation of Cardiac Macrophages in a Model of Dyslipidemia-Induced Diastolic Dysfunction.
Panico C; Felicetta A; Kunderfranco P; Cremonesi M; Salvarani N; Carullo P; Colombo F; Idini A; Passaretti M; Doro R; Rubino M; Villaschi A; Da Rin G; Peano C; Kallikourdis M; Greco CM; Condorelli G
Circulation; 2023 Dec; ():. PubMed ID: 38126199
[TBL] [Abstract][Full Text] [Related]
15. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Myhre PL; Vaduganathan M; Claggett BL; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2022 Dec; 10(12):902-913. PubMed ID: 36114137
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
Yang M; Butt JH; Kondo T; Jering KS; Docherty KF; Jhund PS; de Boer RA; Claggett BL; Desai AS; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Langkilde AM; Martinez FA; Petersson M; Shah SJ; Vaduganathan M; Wilderäng U; Solomon SD; McMurray JJV
Eur J Heart Fail; 2022 Dec; 24(12):2307-2319. PubMed ID: 36342375
[TBL] [Abstract][Full Text] [Related]
17. Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes.
Ryaboshapkina M; Ye R; Ye Y; Birnbaum Y
Cardiovasc Drugs Ther; 2023 Nov; ():. PubMed ID: 37914900
[TBL] [Abstract][Full Text] [Related]
18. Morphometric, Hemodynamic, and Multi-Omics Analyses in Heart Failure Rats with Preserved Ejection Fraction.
Zhang W; Zhang H; Yao W; Li L; Niu P; Huo Y; Tan W
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397533
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.
Chang D; Xu TT; Zhang SJ; Cai Y; Min SD; Zhao Z; Lu CQ; Wang YC; Ju S
Exp Biol Med (Maywood); 2021 Dec; 246(23):2511-2521. PubMed ID: 34342551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
